Biocompatibles Share Discussion Threads

[graham142] 14/7/2006 07:28

Using a software programme called SuperinternetTV I have just watched a program on "The Patient Channel" USA which is presently giving a discussion on the use of drug eluting stents and in general about heart disease - may be interesting for some here...
A link to get the software - 2.8meg -

[tratante] 12/7/2006 10:30

hard to see why BII is in the doldrums given the prospects look good on so many fronts.

[plutonian] 23/6/2006 11:30

This sounds like good news for BII - the competition will get wiped out.

Our drug-eluting stents were designed to be biocompatible and avoid blood clots - That's exactly why they were developed.

Abbott and Medtronic are both licensed to use our PC coating for drug-eluting stents. It sounds like the royalties from these two major companies are going to increase considerably.

[plutonian] 19/6/2006 11:57

* Positive data from PRECISION II (Hong Kong)

* No Myelosuppression or Alopecia in patients from PRECISION I (Barcelona)

* Further data expected at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in September

[plutonian] 19/6/2006 11:51

"Biocompatibles estimates the market opportunity, based on conversion of current TACE procedures to Drug Eluting Bead products, to be around $75m; and the ultimate opportunity in HCC to be worth up to $400m. A conservative estimate of the use of the Drug Eluting bead products in combination with RFA is factored into the $400m number."

[tratante] 13/6/2006 14:53

Despite two pieces of good new in as many weeks we continue to fall. Just reflecting overall market conditions or is their somehting more specific?

[2bob] 08/5/2006 20:48

-->spyder
re#73
"Abbott will surely focus it's attention on their own (wonderful BII) stent"
Zomaxx is not a BII stent. Of the drug/stent/polymer combo BII supply the polymer. If I recall the royalty of the Dexa stent was 6% for which BII supplied the drug, stent, polymer and clinical data. I've lost touch. What is the royalty rate due to BII from the Zomaxx drug stent? Is it 1% ?


"Royalties in the range of one to five per cent. will be payable to
Biocompatibles on the future worldwide sale of drug-eluting cardiovascular
stents (with an additional one per cent. payable in certain circumstances) and
will vary according to the use of the PC coating, the active drug being
delivered and the stent design. The royalties do not apply to non drug-eluting
stents, certain other medical devices covered by the licence agreement and
uncoated drug-eluting stents of a particular design using certain drug
compounds."

[plutonian] 27/4/2006 10:56

Terumo are also launching new products in Europe...

"The DC Bead product will be launched later this year, following positive customer response to the pre-marketing evaluation, performed in 2005. The launch of the PRECISION Bead product is targeted for 2007"

[plutonian] 27/4/2006 10:51

"RITA believes that the total potential U.S. and Canadian market for all
embolization products may be up to $50 million annually, based primarily on the
use of embolization in primary liver cancer patients. RITA currently expects to
begin shipments of the LC Bead in the third quarter of 2006"

So, the current $30m world market is expected to grow to maybe $150m ($50 North America - say the same for Europe - and the same again for everywhere else).

From the finals: "The market leader has a share of approximately 60% and
our goal remains market leadership in a significantly larger market".

[spyder] 20/4/2006 19:53

Abbott will host a special conference call to discuss the Guidant Vascular transaction tomorrow now that it has cleared all regulatory hurdles ........ should be interesting.

spyder

[tratante] 30/3/2006 15:00

Could be on the move again ...

[tratante] 30/3/2006 07:07

Certainly is, now two reasons for Abbott to push their own (BII) stent with Guidant's devices running into problems on two fronts. Could this jeopardise Abbott's takeover of Guidant? In any event it looks good for BII.

[graham142] 29/3/2006 18:40

Is this important?
Guidant to suspend stent, to take charge (8:33 AM ET) NEW YORK (AFX) --
Medical device maker Guidant Corp. said Wednesday it would not release its
current Xience V stent inventory because a small percentage of it was not
manufactured to its quality standards. As a result, Guidant said it voluntarily
stopped enrolling new patients in the 4.0 mm and the Japan arms of the
non-randomized portion of its Spirit III clinical trial, which is designed to
evaluate the safety and efficacy of the Xience V Everolimus Eluting Coronary
Stent System for the treatment of coronary artery disease. Guidant said it would
re-supply units to investigators as soon as new inventory is available. The
company will not utilize existing inventories and will rebuild devices for
SPIRIT III and the upcoming European launch. This will result in a first-quarter
charge of about $15 million to write-off existing Xience V inventory and will
delay the European launch of Xience V until the third quarter of 2006

[tratante] 27/3/2006 10:08

As someone suggested above, they are still tainted with selling off the family silver, people haven't caught on that they are doing big things with the proceeds. An advantage of their approach is that they are about finding ways of delivering existing drugs more effectively so there is less risk here than with novel drug development pharmas. All the results so far have been excellent. Have good potential if they get noticed.

[bigfarmer] 26/3/2006 23:54

You do get the feeling these have been overlooked. Perhaps people not realising that there is still a business in BII.

[2bob] 26/3/2006 13:32

Biomacromolecules. 2006 Mar 13;7(3):784-791.
Controlled Delivery of Antisense Oligodeoxynucleotide from Cationically Modified Phosphorylcholine Polymer Films.

Zhang Z, Cao X, Zhao X, Withers SB, Holt CM, Lewis AL, Lu JR.
Biological Physics Group, School of Physics and Astronomy, The University of Manchester, Sackville Street Building, Sackville Street, Manchester M60 1QD, U.K., Unit of Cardiac Physiology, School of Medicine, 1.305 Stopford Building, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K., and Biocompatibles U.K. Ltd., Farnham, Surrey, GU9 8QL, U.K.

Antisense strategy is a promising approach for the prevention of in-stent restenosis if therapeutic agents such as antisense oligodeoxynucleotides (AS-ODNs) can be successfully delivered to the implant site. Optimizing the routes and conditions for controlled loading and release of therapeutic agents from a biocompatible polymer coating is still required. In this study, phosphorylcholine (PC) polymer films bearing different cationic charge densities were deposited onto smooth silicon substrates. The thickness of these films was determined by spectroscopic ellipsometry (SE). Human c-myc AS-ODNs were incorporated into the PC polymer films by immersion in concentrated AS-ODN solution and eluted into PBS under physiological conditions. The elution profile was monitored by UV spectrometry and gel electrophoresis. Cellular uptake of the eluted AS-ODN into vascular smooth muscle cells (VSMCs) was evaluated by fluorescence microscopy. The results showed that ODN loading capacities increased with film thickness and were also strongly dependent on the cationic charge density. AS-ODN release was characterized by a slight initial burst in the first half hour followed by a period of sustained release up to 8 days. Gel electrophoresis demonstrated DNA integrity, and different transfection efficiencies were observed when the eluted ODNs were transfected into VSMCs. These results demonstrated that cationically modified PC polymers are capable of delivery of antisense ODNs in a controlled manner and that they are well suited for specific biomedical devices such as DNA-eluting stents.

###############################
Expert Opin Drug Deliv. 2006 Mar;3(2):289-98.
PC Technology as a platform for drug delivery: from combination to conjugation.

Lewis AL.

Biocompatibles UK Ltd, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK. [e-mail]

Hydrogel polymers incorporating phosphorylcholine have found widespread use in the manufacture of medical devices with improved haemo- and biocompatibility. Examples include soft contact lenses or coatings for devices, such as coronary stents and extracorporeal circuits. The advent of drug-device combinations has prompted the application of PC Technology (Biocompatibles UK Ltd) as a bioinert drug delivery vehicle, particularly in the form of coatings, for targeted delivery from a device surface. The flexible polymer chemistry employed in the synthesis of these materials offers a range of molecular architectures that could find applicability in a wide variety of drug delivery applications, including micellar, vesicular and gel systems, and even drug conjugation.

[tratante] 23/3/2006 23:44

Welcome Bigfarmer, nice not to be alone! Yes, think you must be right about the update + good results and trial data. Uncertainty about the stent business put to rest too. Current price makes the new bead technology worth about 30p!

[Abuse team] 23/3/2006 14:19

Post removed by ADVFN

[bigfarmer] 23/3/2006 14:17

Piper's update having some effect?

[tratante] 22/3/2006 12:30

nice and steady does it, don't want to scare the horses.

[Abuse team] 21/3/2006 16:11

Post removed by ADVFN

[tratante] 21/3/2006 16:10

Ok, its better being here all by ourselves!

[tratante] 21/3/2006 16:10

yes, but don't say it too loud, someone else may hear and join the BB